Abstract 2271P
Background
An abundance of cancer associated fibroblasts (CAFs) in stromal rich tumours is a barrier to the effectiveness of anticancer therapies. We have developed an oncolytic adenovirus - THEO-260 - that is capable of lysing both cancer cells and CAFs in ovarian patient tumours ex vivo. Here, we present data to support the progression of THEO-260 to first in human (FIH) clinical trials.
Methods
THEO-260 efficacy was assessed in cell lines, multicellular spheroids, ex vivo fresh ovarian patient samples and mouse models bearing human cancers and stromal CAFs. The safety was assessed in primary human normal cells and in immunocompetent mice.
Results
THEO-260 killed a panel of cell lines from ovarian cancer (n=8), in addition to different stromal rich tumour types (pancreatic, colorectal, lung, and breast cancer; n=9) and multicellular spheroids. Moreover, THEO-260 was highly efficacious in fresh ovarian patient materials, killing cancer cells and CAFs in ascites and tumour samples (n=24). THEO-260 outperforms SOC chemotherapies including paclitaxel and PARP inhibitors. In vivo, THEO-260 shows antitumor efficacy, with a complete reduction in tumour volume and is superior to SOC in the platinum resistant ovarian cancer model with human CAFs (COV318+MRC5). THEO-260 also prevents ovarian intraperitoneal metastasis formation in vivo in a human ovarian adenocarcinoma model with CAFs (SKOV3+MRC5). As expected THEO-260 does not replicate in non-human primary cells, supporting replication selectivity testing in normal human primary cells rather than in animal models. THEO-260 demonstrates high selectivity for tumours, with negligible levels of replication and production of infectious virions in all normal primary human cells tested. THEO-260 was also shown to be safe in vivo in immunocompetent mouse models, when tested at repeated and escalating, clinically relevant, dose levels. The genetic and temperature stability of THEO-260 has been confirmed and is currently being GMP manufactured to high yields.
Conclusions
Our data confirms that THEO-260 is efficacious and safe, supporting the initiation of FIH clinical trials in high grade serous ovarian cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Theolytics Ltd.
Funding
Theolytics Ltd.
Disclosure
M. Bazan Peregrino, S.C. Frost, C. Negroni, C. Moriconi, T. Perry, W. Taverner, B. Nicholls, D. Saunders, R. Ackerman-Johnson, A. Lim: Financial Interests, Institutional, Full or part-time Employment: Theolytics Ltd. K. Fisher, M.R. Duffy: Financial Interests, Institutional, Stocks or ownership: Theolytics Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
2295P - Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy
Presenter: Morana Vojnic
Session: Poster session 08
2296P - SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
Presenter: Nicola Maurea
Session: Poster session 08
2297P - Gene co-expression networks capture the potential pathogenesis and progression of upper tract urothelial cancer
Presenter: Tingting Fu
Session: Poster session 08
2298P - Feasibility of ex vivo drug sensitivity testing in urothelial cancer: EVITA trial
Presenter: Mathijs Scholtes
Session: Poster session 08
2299P - Mebendazole enhances the anticancer effect of irinotecan and check-point inhibitor in vitro and in vivo
Presenter: Sharmineh Mansoori
Session: Poster session 08
2300P - Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Presenter: Julieta Rodriguez
Session: Poster session 08
2301P - Combining cancer patient spatial transcriptomics and bulk RNA-Seq data to drive insights into NSCLC
Presenter: Julia Bischof
Session: Poster session 08
2302P - Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays
Presenter: Md Marufur Rahman
Session: Poster session 08
2303P - Protein functional interpretation of gene variants observed in clinical next-generation sequencing (NGS) for pleural mesothelioma
Presenter: Ferdinando Cerciello
Session: Poster session 08
2304P - A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
Presenter: Eun Joo Kang
Session: Poster session 08